Furthermore, down-regulation of ALKBH5 was associated with positive Pembrolizumab or Nivolumab response to PD-1 blockade in melanoma patients, further demonstrating the role of m6A-modified and immune checkpoints in tumor immune evasion [99]. The gene discussed is ALKBH5; the disease is neoplasm.